Published November, 2010
By Dennis M. Brown
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

In their outline and discussion of the use of novel formulation technologies-including synthetic polymers and biomaterials for prolonged or sustained drug release to achieve potentially greater therapeutic effect-they profile those technologies that have resulted in a number of approved and late-stage clinical products.

---

Published November, 2010
By Michael T. Lotze and Michael A. Caligiuri
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology.

---

Published November, 2010
By Randall E. Harris
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

A section on animal models of carcinogenesis presents comprehensive evidence that general NSAIDs inhibit a variety of malignant neoplasms in vivo, and highlights recent findings which show that COX-2 blocking agents produce striking chemopreventive effects against colon cancer and breast cancer as well as other malignancies.

---

Published November, 2010
By Eric Verdin
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

A panel of leading investigators summarizes and synthesizes the new discoveries in the rapidly evolving field of histone acetylation as a key regulatory mechanism for gene expression.

---

Published November, 2010
By Benjamin Bonavida
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance.

---

Published September, 2010
By Rebecca G. Bagley
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes.

---

Published August, 2010
By Vitaly A. Polunovsky, Peter J. Houghton and Vitaly Polunovsky
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island).

---

Published June, 2010
By Benjamin Bonavida
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This monograph will be the first to focus on studies that investigate the role of NO in tumor cell pathogenesis, growth, angiogenesis, response to cytotoxic therapies and NO translational applications in cancer therapy, alone or in conjunction with other therapies.

---

Published November, 2009
By L. Harivardhan Reddy and Patrick Couvreur
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book details the macromolecular therapeutics for cancer therapy. It also covers the classification of these anticancer drugs based on therapeutic targets and elaborates on different classes of anticancer therapeutics.

---

Published September, 2009
By V. Craig Jordan, B.J.A. Furr and JORDAN V. CRAIG
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book describes the principles underlying targeted hormonal treatments, assesses the actions of new and established agents, and illustrates the new applications of hormonal chemoprevention for breast cancer.

---